Keyphrases
Mantle Cell Lymphoma
100%
Ibrutinib
43%
Bruton Tyrosine Kinase Inhibitor
30%
Lymphoma Cells
29%
Bruton's Tyrosine Kinase
27%
Antiproliferative Activity
23%
Anticancer Activity
16%
Overcoming Resistance
13%
Lymphoma Patients
12%
Pyrrol
11%
Cyclin-dependent Kinase 9 (CDK9)
11%
Rituximab
11%
Tumor-immune System
11%
Pyrazolopyrimidine Derivatives
11%
Immune Evolution
11%
Molecular Heterogeneity
11%
Single-cell Profiling
11%
Chemotherapy Resistance
9%
B-cell Lymphoma
9%
Pyrimidine Derivatives
9%
Patient-derived Xenograft
9%
Ibrutinib Resistance
9%
Cell Apoptosis
8%
B-cell Malignancies
8%
Combination Therapy
8%
Pyrrolopyrimidine
8%
Lymphoma
7%
Co-target
7%
Autoimmune Disease
7%
Venetoclax
7%
Chimeric Antigen Receptor T Cells (CAR-T)
7%
Preclinical Development
6%
Clinical Development
6%
Tumor Cells
6%
Glycogen Synthase Kinase 3 (GSK3)
6%
Triazolopyrimidine
6%
Bioinformatics Analysis
6%
Drug Discovery
6%
Structural Optimization
6%
TP53 mutation
6%
Phosphoinositide 3-kinase (PI3K)
6%
IC50 Value
6%
CAR T-cell Therapy
6%
Chimeric Antigen Receptor T-cell Therapy
6%
Apoptosis
5%
Lethality
5%
Glutaminase 1 (GLS1)
5%
Pyrimidone
5%
MALT1
5%
Dihydropyrimidine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Mantle Cell Lymphoma
94%
Ibrutinib
49%
Bruton Tyrosine Kinase
33%
Bruton Tyrosine Kinase Inhibitor
27%
Antiproliferative Activity
19%
Anticancer Drug
18%
Malignant Neoplasm
16%
Protein Kinase B Inhibitor
16%
Cyclin Dependent Kinase 9
16%
Indole
13%
Lead Compound
13%
B Cell Lymphoma
13%
Neoplasm
11%
Rituximab
11%
Piperazine
11%
HIV
11%
Integrase Inhibitor
11%
Protein Kinase B
11%
Chimeric Antigen Receptor
11%
IC50
10%
Pyrimidine Derivative
9%
Combination Therapy
8%
Phosphotransferase Inhibitor
8%
Autoimmune Disease
7%
Histone
7%
Integrase
6%
Prostate Cancer
6%
Lethality
5%
Venetoclax
5%
Chemokine
5%
Isatin Derivative
5%
Salicylamide
5%
Carboxylic Acid Derivative
5%
Androgen Receptor Antagonist
5%
Drug Discovery
5%
Isatin
5%
Promyelocytic Leukemia
5%
Indole Derivative
5%
Cross-Validation
5%
Pyrazolopyrimidine Derivative
5%
Ligase
5%
Protein Arginine Methyltransferase
5%
Virus DNA
5%
Inhibitor of Apoptosis Protein
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Epidermal Growth Factor Receptor
5%
Glutaminase
5%
Pyrazolopyrimidine
5%
Thioredoxin Reductase
5%
Breast Cancer
5%
Medicine and Dentistry
Mantle Cell Lymphoma
77%
Ibrutinib
46%
Bruton Tyrosine Kinase
27%
Bruton Tyrosine Kinase Inhibitor
23%
Protein Kinase B Inhibitor
16%
Programmed Cell Death
16%
Cancer
14%
Mantle Cell Lymphoma Cell
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
13%
Mantle Cell Lymphoma Cell Line
13%
B-Cell Lymphoma
13%
Antiproliferative Activity
12%
Antineoplastic Activity
11%
Piperazine
11%
Cyclin-Dependent Kinase 9
11%
Protein Kinase B
11%
B Cell
10%
Neoplasm
10%
Xenograft
10%
Chimeric Antigen Receptor T-Cell
9%
Pyrimidine
8%
In Vitro
8%
Cell Line
7%
Tumor Cell
7%
Autoimmune Disease
7%
Chimeric Antigen Receptor
6%
Lethality
6%
Receptor
6%
Venetoclax
5%
Glutaminase
5%
Inhibitor of Apoptosis Protein
5%
Personalized Medicine
5%
Skeleton
5%
Cell Cycle Arrest
5%
Cytotoxicity
5%
Cell Cycle Checkpoint
5%
T Cell
5%
Cancer Therapy
5%
Downregulation
5%
Oxidative Phosphorylation
5%
Pyrazolopyrimidine Derivative
5%
Deacetylation
5%
Antibody-Drug Conjugate
5%
Pyrazolopyrimidine
5%
Rituximab
5%
Pyrrolopyrimidine Derivative
5%
Histone
5%
Myeloma
5%
Malignant Neoplasm
5%
Immunity
5%
